Diligence memo · auto-generated · as of July 2, 2026
Romark Laboratories, L.C.
Romark Laboratories, L.C. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Romark Laboratories, L.C. operates in Pharmaceuticals, based in TAMPA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Romark Laboratories, L.C. has raised $116M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $40M on —.
Most recent recorded round closed around 2014-05-27.
Valuation (modeled)modeled
Provath models Romark Laboratories, L.C. at approximately $366M (range $23M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 67 months.
Last raise 12.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 92% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.